Ágnes Simon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ágnes Simon has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Julianna Kardos
Department of Functional Pharmacology, Institute of Molecular Pharmacology, Research Centre of Natural Sciences, Hungarian Academy of Sciences, Hungary
9 shared publications- László Héja
Institute of Organic Chemistry, HUN-REN Research Centre for Natural Sciences, Magyar tudósok körútja 2, 1117 Budapest, Hungary
8 shared publications - István Simon
Institute of Enzymology, Research Centre for Natural Sciences, 1117 Budapest, Hungary
6 shared publications - Julianna Kardos
Department of Neurochemistry, Institute of Biomolecular Chemistry, Chemical Research Center, Hungarian Academy of Sciences, Pusztaszeriút 59-67, 1025 Budapest, Hungary
3 shared publications Júlia Visy
Department of Molecular Pharmacology, Institute of Biomolecular Chemistry
3 shared publicationsLajos Nyikos
Department of Neurochemistry, Institute of Biomolecular Chemistry, Chemical Research Center, Hungarian Academy of Sciences, 1025 Pusztaszeri út 59-67, Budapest, Hungary
3 shared publications
Latest Publications
- Open Access
- 31 December 2022
- Published by Walter de Gruyter GmbH
- p. 476-534
Chapter IX Rolling Transition: Rotating Agency
Chapter IX Rolling Transition: Rotating Agency was published in Rolling Transition and the Role of Intellectuals on page 476.
- 31 December 2022
- Published by Walter de Gruyter GmbH
- p. 476-534
Open AccessChapter IX Rolling Transition: Rotating Agency
Chapter IX Rolling Transition: Rotating Agency was published in Rolling Transition and the Role of Intellectuals on page 476.
- Open Access
- 27 May 2019
- Published by Springer Nature in Molecular Neurobiology
- Vol. 56 (12) , 7950-7965
Molecular Plasticity of the Nucleus Accumbens Revisited—Astrocytic Waves Shall Rise
Part of the ventral striatal division, the nucleus accumbens (NAc) drives the circuit activity of an entire macrosystem about reward like a “flagship,” signaling and leading diverse conducts. Accordingly, NAc neurons feature complex inhibitory phenotypes that assemble to process circuit inputs and generate outputs by exploiting specific arrays of opposite and/or parallel neurotransmitters, neuromodulatory peptides. The resulting complex combinations enable versatile yet specific forms of accumbal circuit plasticity, including maladaptive behaviors. Although reward signaling and behavior are elaborately linked to neuronal circuit activities, it is plausible to propose whether these neuronal ensembles and synaptic islands can be directly controlled by astrocytes, a powerful modulator of neuronal activity. Pioneering studies showed that astrocytes in the NAc sense citrate cycle metabolites and/or ATP and may induce recurrent activation. We argue that the astrocytic calcium, GABA, and Glu signaling and altered sodium and chloride dynamics fundamentally shape metaplasticity by providing active regulatory roles in the synapse- and network-level flexibility of the NAc.
- 27 May 2019
- Published by Springer Nature in Molecular Neurobiology
- Vol. 56 (12) , 7950-7965
Open AccessMolecular Plasticity of the Nucleus Accumbens Revisited—Astrocytic Waves Shall Rise
Part of the ventral striatal division, the nucleus accumbens (NAc) drives the circuit activity of an entire macrosystem about reward like a “flagship,” signaling and leading diverse conducts. Accordingly, NAc neurons feature complex inhibitory phenotypes that assemble to process circuit inputs and generate outputs by exploiting specific arrays of opposite and/or parallel neurotransmitters, neuromodulatory peptides. The resulting complex combinations enable versatile yet specific forms of accumbal circuit plasticity, including maladaptive behaviors. Although reward signaling and behavior are elaborately linked to neuronal circuit activities, it is plausible to propose whether these neuronal ensembles and synaptic islands can be directly controlled by astrocytes, a powerful modulator of neuronal activity. Pioneering studies showed that astrocytes in the NAc sense citrate cycle metabolites and/or ATP and may induce recurrent activation. We argue that the astrocytic calcium, GABA, and Glu signaling and altered sodium and chloride dynamics fundamentally shape metaplasticity by providing active regulatory roles in the synapse- and network-level flexibility of the NAc.
- 1 August 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1828 (8) , 1873-1880
Sodium selective ion channel formation in living cell membranes by polyamidoamine dendrimer
- 1 August 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Biomembranes
- Vol. 1828 (8) , 1873-1880
Sodium selective ion channel formation in living cell membranes by polyamidoamine dendrimer
- Top Cited Papers
- 12 May 2013
- Published by Springer Nature in Nature Chemical Biology
- Vol. 9 (7) , 444-454
Mechanism-based corrector combination restores ΔF508-CFTR folding and function
Compounds that restore function to the cystic fibrosis–linked ΔF508 allele of CFTR can be classified on the basis of three corrector functions, representing different targets within the five domains of the channel protein. Combinations of individual compounds in the three classes can restore considerable function to the mutant channel. The most common cystic fibrosis mutation, ΔF508 in nucleotide binding domain 1 (NBD1), impairs cystic fibrosis transmembrane conductance regulator (CFTR)-coupled domain folding, plasma membrane expression, function and stability. VX-809, a promising investigational corrector of ΔF508-CFTR misprocessing, has limited clinical benefit and an incompletely understood mechanism, hampering drug development. Given the effect of second-site suppressor mutations, robust ΔF508-CFTR correction most likely requires stabilization of NBD1 energetics and the interface between membrane-spanning domains (MSDs) and NBD1, which are both established primary conformational defects. Here we elucidate the molecular targets of available correctors: class I stabilizes the NBD1-MSD1 and NBD1-MSD2 interfaces, and class II targets NBD2. Only chemical chaperones, surrogates of class III correctors, stabilize human ΔF508-NBD1. Although VX-809 can correct missense mutations primarily destabilizing the NBD1-MSD1/2 interface, functional plasma membrane expression of ΔF508-CFTR also requires compounds that counteract the NBD1 and NBD2 stability defects in cystic fibrosis bronchial epithelial cells and intestinal organoids. Thus, the combination of structure-guided correctors represents an effective approach for cystic fibrosis therapy.
- 12 May 2013
- Published by Springer Nature in Nature Chemical Biology
- Vol. 9 (7) , 444-454
Top Cited PapersMechanism-based corrector combination restores ΔF508-CFTR folding and function
Compounds that restore function to the cystic fibrosis–linked ΔF508 allele of CFTR can be classified on the basis of three corrector functions, representing different targets within the five domains of the channel protein. Combinations of individual compounds in the three classes can restore considerable function to the mutant channel. The most common cystic fibrosis mutation, ΔF508 in nucleotide binding domain 1 (NBD1), impairs cystic fibrosis transmembrane conductance regulator (CFTR)-coupled domain folding, plasma membrane expression, function and stability. VX-809, a promising investigational corrector of ΔF508-CFTR misprocessing, has limited clinical benefit and an incompletely understood mechanism, hampering drug development. Given the effect of second-site suppressor mutations, robust ΔF508-CFTR correction most likely requires stabilization of NBD1 energetics and the interface between membrane-spanning domains (MSDs) and NBD1, which are both established primary conformational defects. Here we elucidate the molecular targets of available correctors: class I stabilizes the NBD1-MSD1 and NBD1-MSD2 interfaces, and class II targets NBD2. Only chemical chaperones, surrogates of class III correctors, stabilize human ΔF508-NBD1. Although VX-809 can correct missense mutations primarily destabilizing the NBD1-MSD1/2 interface, functional plasma membrane expression of ΔF508-CFTR also requires compounds that counteract the NBD1 and NBD2 stability defects in cystic fibrosis bronchial epithelial cells and intestinal organoids. Thus, the combination of structure-guided correctors represents an effective approach for cystic fibrosis therapy.
- 1 April 2012
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 50 (3) , 788-795
Characterization of binding mode of imatinib to human α1-acid glycoprotein
- 1 April 2012
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 50 (3) , 788-795
Characterization of binding mode of imatinib to human α1-acid glycoprotein
- 20 June 2011
- Published by Taylor & Francis in Nanotoxicology
- Vol. 6 (6) , 576-586
Assessing toxicity of polyamidoamine dendrimers by neuronal signaling functions
We report for the first time on neuronal signaling for the evaluation of interactions between native plasmamembrane and polyamidoamine (PAMAM) dendrimers. Generation 5 polycationic (G5-NH2), novel β-D-glucopyranose-conjugated G5-NH2 and generation 4.5 polyanionic (G4.5-COONa) polyamidoamine (PAMAM) dendrimers (1–0.0001 mg/ml) were applied in acute brain slices. Functional toxicity assessments–validated by fluorescence imaging of dead cells–were performed by employing electrophysiological indicators of plasma membrane breakdown and synaptic transmission relapse. Irreversible membrane depolarization and decrease of membrane resistance predicted substantial functional neurotoxicity of unmodified G5-NH2, but not of the G4.5-COONa PAMAM dendrimers. Model calculations suggested that freely moving protonated NH2 groups of terminal monomeric units of PAMAM dendrimers may be able directly destroy the membrane or inhibit important K+ channel function via contacting the positively charged NH2. In accordance, conjugation of surface amino groups by β-D-glucopyranose units reduced functional neurotoxicity that may hold great potential for biomedical applications.
- 20 June 2011
- Published by Taylor & Francis in Nanotoxicology
- Vol. 6 (6) , 576-586
Assessing toxicity of polyamidoamine dendrimers by neuronal signaling functions
We report for the first time on neuronal signaling for the evaluation of interactions between native plasmamembrane and polyamidoamine (PAMAM) dendrimers. Generation 5 polycationic (G5-NH2), novel β-D-glucopyranose-conjugated G5-NH2 and generation 4.5 polyanionic (G4.5-COONa) polyamidoamine (PAMAM) dendrimers (1–0.0001 mg/ml) were applied in acute brain slices. Functional toxicity assessments–validated by fluorescence imaging of dead cells–were performed by employing electrophysiological indicators of plasma membrane breakdown and synaptic transmission relapse. Irreversible membrane depolarization and decrease of membrane resistance predicted substantial functional neurotoxicity of unmodified G5-NH2, but not of the G4.5-COONa PAMAM dendrimers. Model calculations suggested that freely moving protonated NH2 groups of terminal monomeric units of PAMAM dendrimers may be able directly destroy the membrane or inhibit important K+ channel function via contacting the positively charged NH2. In accordance, conjugation of surface amino groups by β-D-glucopyranose units reduced functional neurotoxicity that may hold great potential for biomedical applications.
- 24 July 2009
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 385 (2) , 210-214
Substrate–Na+ complex formation: Coupling mechanism for γ-aminobutyrate symporters
- 24 July 2009
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 385 (2) , 210-214
Substrate–Na+ complex formation: Coupling mechanism for γ-aminobutyrate symporters
- 1 December 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (23) , 6290-6292
Validation of high-affinity binding sites for succinic acid through distinguishable binding of gamma-hydroxybutyric acid receptor-specific NCS 382 antipodes
- 1 December 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (23) , 6290-6292
Validation of high-affinity binding sites for succinic acid through distinguishable binding of gamma-hydroxybutyric acid receptor-specific NCS 382 antipodes
- 4 July 2008
- Published by Elsevier in Neuroscience Letters
- Vol. 439 (1) , 66-69
Cyclothiazide binding to the GABAA receptor
- 4 July 2008
- Published by Elsevier in Neuroscience Letters
- Vol. 439 (1) , 66-69
Cyclothiazide binding to the GABAA receptor
- 1 July 2008
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1784 (7-8) , 1106-1114
Organogold complexes probe a large β-barrel cavity for human serum α1-acid glycoprotein
- 1 July 2008
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1784 (7-8) , 1106-1114
Organogold complexes probe a large β-barrel cavity for human serum α1-acid glycoprotein